William Oh, MD: Follow-Up Recommendations During and After Treatment

Video

What type of follow-up is needed for this patient during treatment and afterward?

Historically patients with metastatic prostate cancer would be followed after starting a treatment like leuprolide acetate every three months. As long as they were responding and their PSAs would go down, they may see the urologist or the oncologist while they get their injections, and that type of intensity was really because there was nothing else you could do except the androgen deprivation therapy.

In the setting of docetaxel for hormone-sensitive metastatic prostate cancer, we’re seeing these patients every three weeks obviously, because we’re giving them chemotherapy during that initial period in addition to androgen deprivation therapy. So we’re seeing them much more intensively.


CASE: Metastatic Prostate Cancer (Part 2)

Mathew J is a 61 year old African American male who presented to his primary care physician with lower urinary tract symptoms, including sporadic hematuria. He complains of abdominal pain and low back pain starting four months ago and increasing in frequency. Prior medical history includes non-insulin dependent diabetes mellitus, well-controlled on metformin since 2006. The patient was referred to urology for further evaluation. ng/ml.

During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.

  • Digital rectum exam revealed nodular prostate /L
  • Serum PSA level; 129 ng/ml
  • Alkaline phosphatase, 258
  • TRUS/prostate biopsy: 53 gram prostate, 12/12 cores (+), Gleason 4 + 5
  • CT indicates blastic lesions to lumbar spine and pelvis
  • Bone Scan positive for T/L spine, pelvis, right femur, scapula
  • ECOG performance status, 1

Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content